pipette
ESEspañol

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

Thomas B. Powles, Enrique Grande, Giuseppe Simone, Alfonso Gómez de Liaño, Marco Maruzzo, Pedro Henrique Isaacsson Velho, Eiji Kikuchi, Toan Quang Vu, LAZAR S. POPOVIC, Timuçin Çil, Gwénaëlle Gravis, Robert Radkowski, Luis Raúl Novelo Hernández, Hernán Javier Cutuli, Aristotelis Bamias, Thomas Bauernhofer, Michel Pavic, Yoon Ji Choi, Chao-Hsiang Chang, Hiroshi Kitamura, Jonathan E. Rosenberg, Jacqui Rowbottom, Svetlana Ho, Ashok Gupta, Alexandra Drakaki

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
ConclusionsPerioperative durvalumab with or without tremelimumab plus three cycles of neoadjuvant enfortumab vedotin resulted in significantly better event-free survival outcomes than surgery alone.

Appeared: Monday, October 26. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmoa2608323